Payment overview · 2025
General Payments
$876.52
58 reported records · 17 companies
Healthcare provider profile · identity verified
Shyam Bhaskar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VISALIA, CA · NPI 1194788158
Verified facts
What the public records show
CMS Open Payments records show Shyam Bhaskar, MD received $876.52 in general payments during 2025 across 58 reported records.
GlaxoSmithKline, LLC. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $164.69 | 18.8% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.13 | 18.0% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.35 | 13.8% | 11 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $60.03 | 6.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.13 | 6.4% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $53.03 | 6.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.51 | 4.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.15 | 3.4% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $27.38 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.24 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.78 | 2.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.66 | 2.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.70 | 2.5% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $21.00 | 2.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.46 | 2.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.92 | 2.0% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $17.36 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $834.02 | 57 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $164.69 | 15 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $121.15 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $82.41 | 8 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $60.03 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $53.03 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $53.03 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.02 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.62 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.24 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $30.15 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.66 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 238 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 154 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
238 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 57 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1544 | 455 |
| Levothyroxine Sodium | Levothyroxine Sodium | 631 | 185 |
| Metformin Hcl | Metformin Hcl | 625 | 192 |
| Losartan Potassium | Losartan Potassium | 619 | 186 |
| Ezetimibe | Ezetimibe | 542 | 166 |
| Omeprazole | Omeprazole | 536 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 160 |
| Gabapentin | Gabapentin | 463 | 142 |
| Lisinopril | Lisinopril | 440 | 137 |
| Ozempic | Semaglutide | 377 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 357 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 121 |
| Carvedilol | Carvedilol | 335 | 83 |
| Clopidogrel | Clopidogrel Bisulfate | 322 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 318 | 89 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 88 |
| Potassium Chloride | Potassium Chloride | 283 | 87 |
| Furosemide | Furosemide | 281 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 84 |
| Januvia | Sitagliptin Phosphate | 271 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 257 | 84 |
| Farxiga | Dapagliflozin Propanediol | 238 | 59 |
| Sertraline Hcl | Sertraline Hcl | 236 | 70 |
| Meloxicam | Meloxicam | 233 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 220 | 69 |
| Alendronate Sodium | Alendronate Sodium | 209 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 204 | 63 |
| Eliquis | Apixaban | 197 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 91 |
| Clonazepam | Clonazepam | 191 | 49 |
| Allopurinol | Allopurinol | 172 | 51 |
| Clonidine Hcl | Clonidine Hcl | 172 | 35 |
| Azithromycin | Azithromycin | 162 | 141 |
| Donepezil Hcl | Donepezil Hcl | 162 | 44 |
| Simvastatin | Simvastatin | 161 | 46 |
| Nifedipine Er | Nifedipine | 159 | 49 |
| Montelukast Sodium | Montelukast Sodium | 158 | 46 |
| Enalapril Maleate | Enalapril Maleate | 156 | 48 |
| Jardiance | Empagliflozin | 154 | 41 |
| Atenolol | Atenolol | 139 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 131 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 49 |
| Paroxetine Hcl | Paroxetine Hcl | 124 | 44 |
| Glipizide | Glipizide | 120 | 35 |
| Trazodone Hcl | Trazodone Hcl | 110 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 28 |
| Levetiracetam | Levetiracetam | 98 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 35 |
| Meclizine Hcl | Meclizine Hcl | 92 | 38 |
| Ibuprofen | Ibuprofen | 86 | 32 |
| Tradjenta | Linagliptin | 85 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 22 |
| Baclofen | Baclofen | 81 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 22 |
| Alprazolam | Alprazolam | 80 | 24 |
| Warfarin Sodium | Warfarin Sodium | 79 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 17 |
| Ondansetron Odt | Ondansetron | 76 | 34 |
| Famotidine | Famotidine | 74 | 32 |
| Amiodarone Hcl | Amiodarone Hcl | 73 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 33 |
| Memantine Hcl Er | Memantine Hcl | 71 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 62 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 24 |
| Midodrine Hcl | Midodrine Hcl | 68 | 26 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 20 |
| Cephalexin | Cephalexin | 65 | 50 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 15 |
| Prednisone | Prednisone | 65 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 64 | 58 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | 13 |
| Pregabalin | Pregabalin | 62 | 22 |
| Spironolactone | Spironolactone | 62 | 20 |
| Glimepiride | Glimepiride | 61 | 15 |
| Chlorthalidone | Chlorthalidone | 59 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | 15 |
| Cefuroxime | Cefuroxime Axetil | 55 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 13 |
| Memantine Hcl | Memantine Hcl | 55 | 13 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 55 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 55 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 11 |
| Naproxen | Naproxen | 49 | 25 |
| Ofloxacin | Ofloxacin | 48 | 38 |
| Linzess | Linaclotide | 46 | 13 |
| Lorazepam | Lorazepam | 46 | 24 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Bupropion Xl | Bupropion Hcl | 45 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Propranolol Hcl | Propranolol Hcl | 45 | 13 |
| Xarelto | Rivaroxaban | 45 | 14 |
| Digoxin | Digoxin | 44 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 24 |
| Bumetanide | Bumetanide | 37 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 31 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 16 |
| Calcitriol | Calcitriol | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 31 |
| Irbesartan | Irbesartan | 35 | suppressed |
| Levemir Flexpen | Insulin Detemir | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 12 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Humalog Kwikpen U-100 | Insulin Lispro | 32 | 12 |
| Methotrexate | Methotrexate Sodium | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 31 | 17 |
| Finasteride | Finasteride | 31 | suppressed |
| Glyburide | Glyburide | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 23 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 13 |
| Valsartan | Valsartan | 31 | 13 |
| Clonidine | Clonidine | 30 | suppressed |
| Clotrimazole | Clotrimazole | 29 | 24 |
| Levofloxacin | Levofloxacin | 29 | 23 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Metolazone | Metolazone | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | 12 |
| Colchicine | Colchicine | 21 | 12 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | 11 |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 12 |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Estradiol | Estradiol | 14 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 13 |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Isoniazid | Isoniazid | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $876.52 · 58 records | GlaxoSmithKline, LLC. | AFREZZA, BREZTRI, CREON, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, OFEV, PAXLOVID, RECORLEV, TRELEGY ELLIPTA, VOQUEZNA, VYVGART, VYVGART HYTRULO, Vest Therapy Und, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error